Oramed Pharmaceuticals Inc. (ORMP)
Oramed Pharmaceuticals Inc. engages in the research and development of pharmaceutical solutions with a technology platform for the oral delivery of therapeutic proteins. It develops ORMD-0801, an oral insulin capsule, which is in phase III clinical trial for the treatment of individuals with diabetes. The company has license agreements with Oravax Medical Inc. to commercialize oral vaccines for COVID-19. Oramed Pharmaceuticals Inc. was incorporated in 2002 and is headquartered in New York, New York.
- Symbol
- ORMP
- Exchange
- Nasdaq
- Sector
- Healthcare
- Industry
- Biotechnology
- Market cap
- $196.24M
- 52 week range
- 2.09 - 5.47
Valuation
- Share price
- $4.72 (close of 2026-09-23)
- P/E (TTM)
- 1.12x
- Price to book
- 0.62x
- Price to free cash flow
- -37.63x
- Enterprise value
- $181.73M
- Book value per share
- $7.68
Price performance
| Period | Change |
|---|
| 1 day | +0.43% |
| 5 days | +2.16% |
| 1 month | -1.87% |
| 3 months | +13.19% |
| 6 months | +32.96% |
| Year to date | +65.61% |
| 1 year | +89.56% |
| 3 years | +81.54% |
| 5 years | -78.60% |
| 10 years | -39.80% |
| All time | -40.40% |
Profitability and growth
- Return on equity
- 32.07%
- Return on invested capital
- -9.76%
- Return on assets
- 27.74%
- Return on capital employed
- -7.12%
- Gross margin
- 0.65%
- Net margin
- 3202.50%
- EBITDA margin
- -748.35%
- Net income growth
- 436.04%
- Free cash flow growth
- -8.59%
Cash flow and balance sheet
- Free cash flow yield (TTM)
- -2.66%
- Current ratio
- 4.98x
- Net debt to EBITDA
- -0.23x
Latest reported year
- Period end
- 2025-12-31
- Fiscal year
- 2025
- Revenue
- $2.00M
- Cost of revenue
- $1.99M
- Gross profit
- $13.00K
- EBITDA
- $-14.97M
- Net income
- $64.05M
- Earnings per share
- $1.53
- Research and development
- $6.38M
- Shares outstanding
- 41.40M
Income statement by year
| Period end | Revenue | Gross profit | Net income | EPS |
|---|
| 2025-12-31 | $2.00M | $13.00K | $64.05M | $1.53 |
| 2024-12-31 | - | - | $-19.06M | $-0.48 |
| 2023-12-31 | $1.34M | - | $5.09M | $0.14 |
| 2022-12-31 | $2.70M | $852.00K | $-36.56M | $-0.94 |
| 2021-08-31 | $2.70M | - | $-22.99M | $0.78 |
| 2020-08-31 | $2.71M | - | $-11.51M | $0.56 |
| 2019-08-31 | $2.70M | $2.61M | $-14.36M | $0.82 |
| 2018-08-31 | $2.45M | - | $-12.73M | $0.86 |
| 2017-08-31 | $2.46M | $2.27M | $-10.48M | $0.79 |
| 2016-08-31 | $641.00K | $151.00K | $-10.96M | $0.87 |
Margins and returns by year
| Period end | Gross margin | Net margin | Return on equity | Return on capital |
|---|
| 2025-12-31 | 0.65% | 3202.50% | 32.07% | -9.76% |
| 2024-12-31 | - | - | -13.11% | -14.00% |
| 2023-12-31 | - | 379.70% | 3.12% | -10.67% |
| 2022-12-31 | 31.52% | -1352.61% | -24.19% | -36.38% |
| 2021-08-31 | - | -850.50% | -19.73% | -60.85% |
| 2020-08-31 | - | -424.76% | -35.01% | -113.48% |
| 2019-08-31 | 96.67% | -531.08% | -74.02% | -51.17% |
| 2018-08-31 | - | -519.68% | -40.91% | -33.86% |
| 2017-08-31 | 92.39% | -426.71% | -54.48% | -70.54% |
| 2016-08-31 | 23.56% | -1710.45% | -41.86% | -44.92% |
Cash and debt by year
| Period end | Cash | Debt |
|---|
| 2025-12-31 | $45.95M | - |
| 2024-12-31 | $54.42M | - |
| 2023-12-31 | $66.77M | - |
| 2022-12-31 | $40.46M | $25.00K |
| 2021-08-31 | $77.25M | - |
| 2020-08-31 | $22.59M | - |
| 2019-08-31 | $3.33M | $9.66M |
| 2018-08-31 | $5.00M | $11.39M |
| 2017-08-31 | $3.97M | - |
| 2016-08-31 | $3.91M | - |
Free cash flow by year
| Period end | Free cash flow | Stock-based compensation |
|---|
| 2025-12-31 | $-9.15M | $5.99M |
| 2024-12-31 | $-8.43M | $4.05M |
| 2023-12-31 | $-10.55M | $4.21M |
| 2022-12-31 | $-28.41M | $11.51M |
| 2021-08-31 | $-21.56M | $2.69M |
| 2020-08-31 | $-12.52M | $465.00K |
| 2019-08-31 | $-12.96M | $808.00K |
| 2018-08-31 | $-14.66M | $1.55M |
| 2017-08-31 | $-5.84M | $1.57M |
| 2016-08-31 | $4.65M | $634.00K |
Dividend history
- Most recent payment
- 2026-01-16
- Paid in the last twelve months
- $0.25
| Payment date | Dividend per share |
|---|
| 2026-01-16 | $0.25 |
Investor relations
Next earnings report
- Next confirmed report
- 2026-11-12
- Consensus EPS estimate
- $0.43
Past earnings dates
| Reported | Fiscal period | EPS estimate |
|---|
| 2026-05-19 | Mar/2026 | - |
| 2026-03-26 | - | - |
| 2025-11-13 | - | - |
| 2025-08-14 | - | - |
| 2025-05-15 | - | - |
| 2025-03-27 | - | - |
| 2024-11-07 | - | - |
| 2024-08-14 | - | - |
Filings and sources
- Company website
- oramed.com
- SEC filings
- 10-K, 10-Q and 8-K on EDGAR
- Earnings calendar
- All upcoming reports
Similar companies
Vertex Pharmaceuticals Inc (VRTX) · Regeneron Pharmaceuticals, Inc. (REGN) · Moderna, Inc. (MRNA) · Incyte Corp (INCY) · Bio-Techne Corp (TECH) · Thermo Fisher Scientific Inc. (TMO) · Danaher Corp (DHR) · IQVIA Holdings Inc. (IQV)
All Healthcare companies
Understanding these figures
Price-to-earnings ratio · Discounted cash flow · Free cash flow · Earnings per share · Return on equity · Gross margin vs net margin · Reading a balance sheet · Debt and leverage · Dividend yield · Insider transactions and Form 4 · How to read a stock chart
Explore
Company directory · S&P 500 heatmap · Earnings calendar · Super investor holdings · Congress trades